Revelation Biosciences, Inc. (REVBW)

USD 0.01

(21.95%)

Market Cap (In USD)

2.81 Million

Revenue (In USD)

-

Net Income (In USD)

-120.25 Thousand

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.01-0.01
PE
-
EPS
-
Beta Value
0.153
ISIN
US76135L1199
CUSIP
76135L119
CIK
1810560
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. James M. Rolke
Employee Count
-
Website
https://www.revbiosciences.com
Ipo Date
Details
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.